You just read:

EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

News provided by

Daiichi Sankyo Company, Limited

Nov 05, 2018, 02:00 ET